In this study, a total of 198 treatment-naïve patients with EGFR-mutant advanced NSCLC and initial brain metastasis treated with gefitinib, erlotinib, and afatinib were included and the CNS response rate of gefitinib, erlotinib, and afatinib were reported as 64.7%, 68.2%, and 72.9%, respectively (P = 0.78). Here, EGFR is linked to non-small cell lung carcinoma.